Androgen deprivation therapy and cardiovascular risk in Chinese patients with nonmetastatic carcinoma of prostate

Journal of Oncology

Volumn 2014, Issue , 2014, Pages

  Huang, Gang ^a,b   Yeung, Chun Yip ^a   Lee, Ka Kui ^a   Liu, Jianxiong ^b   Ho, Kwan Lun ^a   Yiu, Ming Kwong ^a   Lam, Karen Siu Ling ^a   Tse, Hung Fat ^a   Yau, Thomas ^a   Siu, Chung Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Second People's Hospital of Chengdu   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHINESE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROSTATE CARCINOMA;

EID: 84900015927     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2014/529468     Document Type: Article

References (26)

1. Hussain S., Gunnell D., Donovan J., McPhail S., Hamdy F., Neal D., Albertsen P., Verne J., Stephens P., Trotter C., Martin R. M., Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. British Journal of Urology International 2008 101 5 547 555 2-s2.0-38849168891 10.1111/j.1464-410X.2007.07338.x
2. Bray F., Lortet-Tieulent J., Ferlay J., Forman D., Auvinen A., Prostate cancer incidence and mortality trends in 37 European countries: an overview. European Journal of Cancer 2010 46 17 3040 3052 2-s2.0-78049470983 10.1016/j.ejca.2010.09.013
3. Kvåle R., Auvinen A., Adami H.-O., Klint Å., Hernes E., Møller B., Pukkala E., Storm H. H., Tryggvadottir L., Tretli S., Wahlqvist R., Weiderpass E., Bray F., Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. Journal of the National Cancer Institute 2007 99 24 1881 1887 2-s2.0-38449102006 10.1093/jnci/djm249
4. Nguyen P. L., Je Y., Schutz F. A. B., Hoffman K. E., Hu J. C., Parekh A., Beckman J. A., Choueiri T. K., Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Journal of the American Medical Association 2011 306 21 2359 2366 2-s2.0-83055163746 10.1001/jama.2011.1745
5. Keating N. L., O'Malley A. J., Smith M. R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 2006 24 27 4448 4456 2-s2.0-33749058933 10.1200/JCO.2006.06. 2497
6. Keating N. L., O'Malley A. J., Freedland S. J., Smith M. R., Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute 2010 102 1 39 46 2-s2.0-74049152290 10.1093/jnci/djp404
7. Alibhai S. M. H., Duong-Hua M., Sutradhar R., Fleshner N. E., Warde P., Cheung A. M., Paszat L. F., Impact of androgen deprivation therapy on cardiovascular disease and diabetes. Journal of Clinical Oncology 2009 27 21 3452 3458 2-s2.0-70249149328 10.1200/JCO.2008.20.0923
8. Punnen S., Cooperberg M. R., Sadetsky N., Carroll P. R., Androgen deprivation therapy and cardiovascular risk. Journal of Clinical Oncology 2011 29 26 3510 3516 2-s2.0-80053029103 10.1200/JCO.2011.35.1494
9. Tsai H. K., D'Amico A. V., Sadetsky N., Chen M.-H., Carroll P. R., Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute 2007 99 20 1516 1524 2-s2.0-35548937873 10.1093/jnci/djm168
10. Saigal C. S., Gore J. L., Krupski T. L., Hanley J., Schonlau M., Litwin M. S., Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 110 7 1493 1500 2-s2.0-34648828214 10.1002/cncr.22933
11. Efstathiou J. A., Bae K., Shipley W. U., Hanks G. E., Pilepich M. V., Sandler H. M., Smith M. R., Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85-31. Journal of Clinical Oncology 2009 27 1 92 99 2-s2.0-58149337570 10.1200/JCO.2007.12.3752
12. Roach M. III, Bae K., Speight J., Wolkov H. B., Rubin P., Lee R. J., Lawton C., Valicenti R., Grignon D., Pilepich M. V., Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. Journal of Clinical Oncology 2008 26 4 585 591 2-s2.0-39149085396 10.1200/JCO.2007.13.9881
13. Bolla M., de Reijke T. M., van Tienhoven G., Van Den Bergh A. C. M., Oddens J., Poortmans P. M. P., Gez E., Kil P., Akdas A., Soete G., Kariakine O., Van Der Steen-Banasik E. M., Musat E., Piérart M., Mauer M. E., Collette L., Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine 2009 360 24 2516 2527 2-s2.0-67149125847 10.1056/NEJMoa0810095
14. D'Amico A. V., Chen M.-H., Renshaw A. A., Loffredo M., Kantoff P. W., Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Journal of the American Medical Association 2008 299 3 289 295 2-s2.0-38349164176 10.1001/jama.299.3.289
15. Messing E. M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., di'SantAgnese P. A., Trump D., Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet Oncology 2006 7 6 472 479 2-s2.0-33646866593 10.1016/S1470-2045(06)70700-8
16. Bolla M., van Tienhoven G., Warde P., Dubois J. B., Mirimanoff R.-O., Storme G., Bernier J., Kuten A., Sternberg C., Billiet I., Torecilla J. L., Pfeffer R., Cutajar C. L., Van der Kwast T., Collette L., External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet Oncology 2010 11 11 1066 1073 2-s2.0-78049527402 10.1016/S1470-2045(10)70223-0
17. Schröder F. H., Kurth K.-H., Fossa S. D., Hoekstra W., Karthaus P. P., De Prijck L., Collette L., Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). European Urology 2009 55 1 14 22 2-s2.0-56249134154 10.1016/j.eururo.2008.09.008
18. Studer U. E., Whelan P., Albrecht W., Casselman J., De Reijke T., Hauri D., Loidl W., Isorna S., Sundaram S. K., Debois M., Collette L., Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891. Journal of Clinical Oncology 2006 24 12 1868 1876 2-s2.0-33646360629 10.1200/JCO.2005.04.7423
19. Denham J. W., Steigler A., Lamb D. S., Joseph D., Turner S., Matthews J., Atkinson C., North J., Christie D., Spry N. A., Tai K.-H., Wynne C., D'Este C., Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology 2011 12 5 451 459 2-s2.0-79955470908 10.1016/S1470-2045(11) 70063-8
20. Aus G., Abrahamsson P.-A., Ahlgren G., Hugosson J., Lundberg S., Schain M., Schelin S., Pedersen K., Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. British Journal of Urology International 2002 90 6 561 566 2-s2.0-0036381078 10.1046/j.1464-410X.2002.02982.x
21. Schulman C. C., Debruyne F. M. J., Forster G., Selvaggi F. P., Zlotta A. R., Witjes W. P. J., 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Urology 2000 38 6 706 713 2-s2.0-0033662583
22. Yee D. S., Lowrance W. T., Eastham J. A., Maschino A. C., Cronin A. M., Rabbani F., Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. British Journal of Urology International 2010 105 2 185 190 2-s2.0-74049164745 10.1111/j.1464-410X.2009. 08698.x
23. Nguyen P. L., Androgen-deprivation therapy and cardiovascular harm: let's not throw out the baby with the bathwater. European Urology 2013
24. Nanda A., Chen M.-H., Braccioforte M. H., Moran B. J., D'Amico A. V., Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. Journal of the American Medical Association 2009 302 8 866 873 2-s2.0-69249229866 10.1001/jama.2009.1137
25. Vigen R., O'Donnell C. I., Barn A. E., Grunwald G. K., Maddox T. M., Bradley S. M., Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. Journal of the American Medical Association 2013 310 17 1829 1836 10.1001/jama.2013.280386
26. Levine G. N., D'Amico A. V., Berger P., Clark P. E., Eckel R. H., Keating N. L., Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010 121 6 833 840